BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCT - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCT
X-ORIGINAL-URL:https://bioct.org
X-WR-CALDESC:Events for BioCT
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261001T110000
DTEND;TZID=America/New_York:20261001T120000
DTSTAMP:20260924T195705Z
CREATED:20260924T195705Z
LAST-MODIFIED:20260924T195705Z
UID:10003131-1790852400-1790856000@bioct.org
SUMMARY:Is Targeted Protein Degradation the “Break” Neurology Needs? - Hosted by GEN
DESCRIPTION:Neurodegenerative diseases such as Alzheimer’s and Parkinson’s remain some of the most challenging conditions to treat. Despite decades of research\, small molecule inhibitors have shown limited clinical benefit for treating misfolded proteins\, while amyloid-beta-focused approaches have been shown to address only one of many underlying disease drivers. Repeated late-stage failures have underscored the biological complexity of these disorders. \nTargeted protein degradation is emerging as a promising modality for eliminating disease-driving proteins. By selectively reducing pathogenic protein levels\, degraders may offer a way to address neurodegenerative and neuromuscular diseases by targeting proteins that lack conventional druggable sites. \nIn this GEN webinar\, our expert speaker will discuss the increasing rationale for targeting key drivers of neurological disease with protein degraders and how this approach may enable deeper\, more precise modulation of disease biology. Key takeaways from the webinar will include: \n\nTargeted protein degradation could help address the underlying biology of neurodegenerative and neuromuscular diseases.\nProtein degraders are designed to selectively eliminate disease-driving proteins that have historically been difficult or impossible to target\, potentially expanding the range of tractable targets in neurology.\nIn preclinical experiments\, certain protein degraders have shown the ability to reach the target in the brain or muscle\, reduce the disease-associated protein\, and affect downstream biological pathways.\n\nSpeaker: \nAngela M. Cacace\, PhD \nDr. Angela Cacace serves as Chief Scientific Officer (CSO) at Arvinas. Prior to her role as CSO\, Dr. Cacace most recently served as Senior Vice President\, Neuroscience and Platform Biology. Dr. Cacace has three decades of drug discovery experience in neuroscience and oncology research across modalities. During her time at Arvinas\, Dr. Cacace has led the continuous evolution of our PROTAC Discovery Engine to employ new E3 ligases and cross the blood-brain barrier for multiple neurologic disease targets. \nPreviously\, Dr. Cacace served as the Vice President of Biology at Fulcrum Therapeutics\, where she built the biology platform\, grew talented scientific teams\, delivered the first development candidates\, and guided the development of translational biomarkers to enable clinical development programs. \nAdditionally\, Dr. Cacace served in positions of increasing responsibility at Bristol Myers Squibb\, including as the Director of Neuroscience and Genetically Defined Diseases\, where she spearheaded alternative therapeutic modalities and was a co-inventor on several development candidates. Throughout her time at Bristol Myers Squibb\, she was responsible for building research-wide teams and initiatives\, including the Lead Discovery and Optimization functions. While serving as a Sr. Principal Scientist in Cancer Biology at Pfizer\, together with her team\, she discovered a novel anti-angiogenic antibody development candidate. Dr. Cacace currently serves on the Board of Directors for BioCT.
URL:https://bioct.org/event/is-targeted-protein-degradation-the-break-neurology-needs-hosted-by-gen/
LOCATION:VIRTUAL
END:VEVENT
END:VCALENDAR